Kidney syndrome hemorrhagic fever Vero cell bivalent purified vaccine and industrialized producing process thereof

Abstract

The invention involves nephrotic syndrome hemorrhagic fever Vero cells purified bivalent vaccine and its industrialized preparation methods. The nephrotic syndrome hemorrhagic fever Vero cells bivalent purified vaccine in the inventioncontains effective doses of nephrotic syndrome hemorrhagic fever deactive virus type I, type II and vaccine adjuvants, the type I and type II virus are from PS-6 (C-3) strains, CCTCC-V200503 and L99(C-2) strains, CCTCC-V200504 respectively. The preparation method of the invention includes: 1. Preparating the vaccine stock solution nephrotic syndrome hemorrhagic fever virus PS-6(C-3), CCTCC-V200503 and L99(C-2),CCTCC-V200504, inactivating virus with formaldehyde; 2. combining the deactive vaccine stock solution of PS-6(C-3), CCTCC-V200503 and L99(C-2),CCTCC-V200504 and purifying, the process contains centrifugal separation, hyperfiltration, concentration, zinc acetate deposition and column chromatography; 3. adding adjuvant into the purified vaccine stock solution and getting the purified bivalent vaccine. The nephrotic syndrome hemorrhagic fever Vero cells purified bivalent vaccine in the invention is suitable for the prevention of nephrotic syndrome hemorrhagic fever mainly based on all type I and type II.

Description

technical field [0001] The invention relates to a bivalent purified vaccine of hemorrhagic fever with renal syndrome Vero cells and an industrial production method of the purified vaccine. Background technique [0002] Hemorrhagic fever with renal syndrome (epidemic hemorrhagic fever) is a viral acute infectious disease, which is extremely harmful to human health. In China, representative hemorrhagic fever with renal syndrome virus strains include, for example, PS-6 (type I), L99 (type II), JR-C-1 and so on. [0003] For a long time, people have been devoting themselves to the development of vaccines for hemorrhagic fever with renal syndrome, especially bivalent or multivalent vaccines against type I and type II hemorrhagic fever with renal syndrome. [0004] Chinese patent application, publication number: CN1236646A, discloses a kind of primary generation hamster kidney cell polyvalent purified vaccine of epidemic hemorrhagic fever (Changchun Institute of Biological Produc...

AI Technical Summary

Problems solved by technology

[0006] Chinese patent application, publication number: CN1237456A, has introduced a kind of epidemic hemorrhagic fever cell multivalent purification vaccine (Chinese Academy of Preventive Medicine Institute of Virology), wherein Vero cells are used for final dilution and alternate passage of suckling white mouse brain Method to prepare virus seed, to produce the polyvalent purified vaccine of epidemic hemorrhagic fever, but the virulence of the virus seed selected by this method is only 7.0LgCCID50 / ml, and the number of harvests of virus liquid is seldom (3 times) , making the cost of industrial production of vaccines too high

Images